Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cefuroxime
Drug ID BADD_D00407
Description Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.
Indications and Usage For the treatment of many different types of bacterial infections such as bronchitis, sinusitis, tonsillitis, ear infections, skin infections, gonorrhea, and urinary tract infections.
Marketing Status approved
ATC Code J01DC02; S01AA27
DrugBank ID DB01112
KEGG ID D00262
MeSH ID D002444
PubChem ID 41375
TTD Drug ID D0Y2IE
NDC Product Code 0143-9567; 0143-9569; 0143-9976; 0143-9568; 0143-9977; 0143-9979
UNII O1R9FJ93ED
Synonyms Cefuroxime | Cephuroxime | Zinacef | Ketocef
Chemical Information
Molecular Formula C16H16N4O8S
CAS Registry Number 55268-75-2
SMILES CON=C(C1=CC=CO1)C(=O)NC2C3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Stress cardiomyopathy24.04.04.026; 02.04.01.0120.000215%Not Available
Foetal hypokinesia18.03.02.0150.000286%Not Available
Subretinal fluid12.01.04.031; 06.09.03.0270.000215%Not Available
Cutaneous symptom23.07.04.0230.000215%Not Available
Macular detachment06.09.03.0200.002003%Not Available
Fine motor skill dysfunction17.01.02.0200.000143%Not Available
Cross sensitivity reaction10.01.01.0360.000787%Not Available
Delayed dark adaptation06.02.06.0210.001216%Not Available
Dyschromatopsia06.02.09.0030.000143%Not Available
Dyskinesia neonatal18.04.04.014; 17.01.02.0290.000143%Not Available
Gait inability17.02.05.069; 08.01.02.011--Not Available
Haemophagocytic lymphohistiocytosis16.32.03.038; 10.02.01.077; 01.05.01.0260.000143%Not Available
Larynx irritation22.04.01.0150.000143%Not Available
Neonatal dyspnoea22.11.01.012; 18.04.09.012; 02.11.05.0080.000143%Not Available
Periorbital fat herniation06.08.03.0300.000143%Not Available
Pulmonary necrosis22.01.02.0350.000143%Not Available
Retinal drusen06.09.03.0340.000143%Not Available
Serous retinal detachment06.09.03.0370.001216%Not Available
Symmetrical drug-related intertriginous and flexural exanthema23.03.05.012; 10.01.01.0460.000386%Not Available
Taste disorder17.02.07.029; 07.14.03.0040.000386%Not Available
Vulvovaginal inflammation21.14.02.014--Not Available
The 13th Page    First    Pre   13    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene